Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-17T23:27:32.631Z Has data issue: false hasContentIssue false
  • English
  • Français

Induction chemotherapy with S-1 plus cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck

Published online by Cambridge University Press:  30 November 2007

Y J Choi ,
J S Chung ,
H-J Shin ,
G J Cho ,
S G Wang ,
B J Lee ,
B M Cho ,
Y D Joo  and
C H Sohn
Y J Choi*
Affiliation:
Department of Hemato-oncology, Pusan National University Hospital, Busan, Republic Of Korea
J S Chung
Affiliation:
Department of Hemato-oncology, Pusan National University Hospital, Busan, Republic Of Korea
H-J Shin
Affiliation:
Department of Hemato-oncology, Pusan National University Hospital, Busan, Republic Of Korea
G J Cho
Affiliation:
Department of Hemato-oncology, Pusan National University Hospital, Busan, Republic Of Korea
S G Wang
Affiliation:
Department of Otolaryngology, Pusan National University Hospital, Busan, Republic Of Korea
B J Lee
Affiliation:
Department of Otolaryngology, Pusan National University Hospital, Busan, Republic Of Korea
B M Cho
Affiliation:
Department of Preventive Medicine, Pusan National University Hospital, Busan, Republic Of Korea
Y D Joo
Affiliation:
Department of Hemato-oncology, Inje University Hospital, Busan, Republic of Korea
C H Sohn
Affiliation:
Department of Hemato-oncology, Inje University Hospital, Busan, Republic of Korea
*
Address for correspondence: Professor Jooseop Chung, Department of Hematology-oncology, Pusan National University Hospital, 1-10 Ami-Dong, Seo-Gu, Busan 602-739, South Korea. Fax: 82 51 254 3127 E-mail: porori701@hanmail.net
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

This study was performed to assess the efficacy and safety profile of combination treatment with S-1 and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck.

Design:

Eligibility criteria comprised: histologically confirmed squamous cell carcinoma of the head and neck; stage three or four disease with no evidence of distant metastasis; evaluable lesions; adequate organ function; age 20–80 years; and a performance status of two or less. Cisplatin was infused over one hour on day one (75 mg/m2) and S-1 was administered orally for 14 consecutive days (days two to 15). The dosages of S-1 were calculated according to the patients' body surface area: 50 mg twice a day (body surface area <1.5 m2) or 60 mg twice a day (body surface area >1.5 m2). Each course was repeated every three weeks. After two courses, tumour response was evaluated by computed tomography and laryngoscopy. If a response was evident (either complete or partial), the patient received one more course of chemotherapy, before undergoing radical treatment such as radiotherapy or surgery.

Results:

All 30 patients were assessable for toxicity, and 29 patients for treatment response. The overall response was 89.7 per cent (complete response: nine; partial response: 17). The two-year estimated overall survival rate was 79.2 per cent. Adverse reactions occurred 128 times during 81 courses in the 30 cases. The most common grade three to four adverse event was neutropenia, which occurred in eight patients. Cases of non-haematological grade three or four toxicity included nausea and vomiting in four patients, stomatitis in two and diarrhoea in one.

Conclusion:

S-1 plus cisplatin combination chemotherapy is effective against locally advanced squamous cell carcinoma of the head and neck, with only mild toxicity.

Keywords

Head and Neck NeoplasmsAnti-Neoplastic AgentsCisplatinToxicity
Type
Main Article
Information
The Journal of Laryngology & Otology , Volume 122 , Issue 8 , August 2008 , pp. 848 - 853
Copyright
Copyright © JLO (1984) Limited 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Forastiere, AA, Koch, W, Trotti, A, Sidransky, D. Medical progress: head and neck cancer. N Engl J Med 2001;345:1890–900CrossRefGoogle Scholar
2Posner, MR, Haddad, RI, Wirth, L, Norris, MR, Goguen, LA, Mahadevan, A et al. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol 2004;31:778–85CrossRefGoogle ScholarPubMed
3Pignon, JP, Bourhis, J, Domenge, C, Designe, L. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949–55CrossRefGoogle Scholar
4Lefebvre, JL, Chevalier, D, Luboinski, B, Kirkpatrick, A, Collete, L, Sahmoud, T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 1996;88:890–8CrossRefGoogle ScholarPubMed
5Forastiere, AA, Goepfert, H, Maor, M, Pajak, TF, Weber, R, Morrisson, W et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091–8CrossRefGoogle ScholarPubMed
6Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685–9CrossRefGoogle Scholar
7Calais, G, Alfonsi, M, Bardet, E, Sire, C, Germain, T, Bergerot, P et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081–6CrossRefGoogle ScholarPubMed
8Depondt, J, Gehanno, P, Martin, M, Leievre, G, Guerrier, B, Peytral, S et al. Neoadjuvant chemotherapy with carboplatin/5-fluorouracil in head and neck cancer. Oncology 1993;50:23–7CrossRefGoogle ScholarPubMed
9Domenge, C, Hill, C, Lefebvre, JL, De Raucourt, D, Rhein, B, Wibault, P et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. Br J Cancer 2000;83:1594–8CrossRefGoogle ScholarPubMed
10Monnerat, C, Faivre, S, Temam, S, Bourhis, J, Raymond, E. End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol 2002;13:995–1006CrossRefGoogle ScholarPubMed
11Rooney, M, Kish, J, Jacobs, J, Kinzie, J, Weaver, A, Crissman, J et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 1985;55:1123–83.0.CO;2-8>CrossRefGoogle ScholarPubMed
12Janinis, J, Papadakou, M, Panagos, G, Panousaki, A, Georgoulias, V, Hatzidaki, D et al. Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Clin Oncol 2001;24:227–31CrossRefGoogle ScholarPubMed
13Schrijvers, D, Van Herpen, C, Kerger, J, Joosens, E, Van Laser, C, Awada, A et al. Docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I–II feasibility study. Ann Oncol 2004;15:638–45CrossRefGoogle ScholarPubMed
14Tsukuda, M, Mikami, Y, Tanigaki, Y, Katori, H, Horiuchi, C, Ikeda, Y et al. Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck. Int J Clin Oncol 2004;9:161–6CrossRefGoogle ScholarPubMed
15Watanabe, A, Taniguchi, M, Sasaki, S. Induction chemotherapy with docetaxel, cisplatin, fluorouracil and 1-leucovorin for locally advanced head and neck cancer: a modified regimen for Japanese patients. Anticancer Drugs 2003;14:801–7CrossRefGoogle Scholar
16Schoffski, P. The modulated oral fluropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs 2004;15:85–106CrossRefGoogle Scholar
17Shirasaka, T, Nakano, K, Takechi, T, Satake, H, Uchida, J, Fujioka, A et al. Antitumor activity of 1Mtegafur-0.4M5-chloro-2,4dihydroxypyridine-1Mpotassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996;56:2602–6Google ScholarPubMed
18Shirasaka, T, Shimamoto, Y, Fukushima, M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993;53:4004–9Google ScholarPubMed
19Inuyama, Y, Kida, A, Tsukuda, M, Kohno, N, Satake, B. Late phase II study of S-1 in patients with advanced head and neck cancer [in Japanese]. Gan To Kagaku Ryoho 2001;28:1381–90Google ScholarPubMed
20Perez, A, Brady, W. Chemoirradiation in head and neck cancer: a review – part I. PRRO Updates 2(2), 2001; Part II. Lippincott Williams and Wilkins PRRO updates 2(3), 2001Google Scholar
21Posner, MR, Colevas, AD, Tishler, RB. The role of induction chemotherapy in the curative treatment of squamous cell carcinoma of the head and neck. Semin Oncol 2000;27(suppl G):13–24Google Scholar
22Posner, MR, Glisson, B, Frenette, G, Al-Sarrat, M, Colevas, AD, Norris, CM et al. A multi-center phase I–II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2001;19:1096–104CrossRefGoogle Scholar
23Spaulding, B, Fischer, G, Wolf, T. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. J Clin Oncol 1994;12:1592–9CrossRefGoogle ScholarPubMed
24Specht, L, Larsen, SK, Hansen, HS. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck. Ann Oncol 2000;11:845–9CrossRefGoogle ScholarPubMed
25Fonseca, E, Grau, JJ, Stastre, J, Garcia-Gomez, JM, Rueda, A, Pastor, M et al. Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: a randomised phase II study. Eur J Cancer 2005;41:1254–60CrossRefGoogle ScholarPubMed